ID
11735
Descripción
The study is designed to assess safety and effects of vorapaxar, when added to standard of care (aspirin and clopidigrel), in Japanese subjects with acute coronary syndrome. The study may also provide information about the effect of vorapaxar on preventing heart attack and stroke in this subject population.
Palabras clave
Versiones (2)
- 28/7/15 28/7/15 -
- 21/11/15 21/11/15 -
Subido en
28 de julio de 2015
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY-NC 3.0 Legacy
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Eligibility Criteria: Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)
Eligibility criteria
- StudyEvent: ODM
Descripción
Exclusion Criteria
Descripción
Pregnant and nursing mothers (premenopausal women should have a negative pregnancy test result confirmed before enrollment)
Tipo de datos
boolean
Alias
- UMLS CUI-1
- C0549206
Descripción
known hypersensitivity to any component of the current investigational product;
Tipo de datos
boolean
Alias
- UMLS CUI-1
- C0013182
Descripción
Participation in a study of experimental therapy or use of any investigational drug within 30 days before enrollment
Tipo de datos
boolean
Alias
- UMLS CUI-1
- C0422740
Descripción
History of a bleeding diathesis
Tipo de datos
boolean
Alias
- UMLS CUI-1
- C3251812
Descripción
evidence of active abnormal bleeding within 30 days before enrollment
Tipo de datos
boolean
Alias
- UMLS CUI-1
- C0019080
Descripción
History of a hemorrhagic stroke at any time
Tipo de datos
boolean
Alias
- UMLS CUI-1
- C0559159
Descripción
Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) while receiving therapy;
Tipo de datos
boolean
Alias
- UMLS CUI-1
- C0020538
Descripción
Major surgery within 2 weeks prior to enrollment
Tipo de datos
boolean
Alias
- UMLS CUI-1
- C0679637
Descripción
Known platelet count <100,000/mm^3
Tipo de datos
boolean
Alias
- UMLS CUI-1
- C0032181
Descripción
Uncontrolled cardiac arrhythmia;
Tipo de datos
boolean
Alias
- UMLS CUI-1
- C0003811
Descripción
Known impairment of renal function (serum creatinine >2.0 mg/dL [>176.8 umol/L]), dysproteinemia, nephrotic syndrome, or other renal disease;
Tipo de datos
boolean
Alias
- UMLS CUI-1
- C0035078
Descripción
Active or chronic hepatobiliary or hepatic disease
Tipo de datos
boolean
Alias
- UMLS CUI-1
- C0085605
Descripción
Anticipated staged PCI
Tipo de datos
boolean
Alias
- UMLS CUI-1
- C1532338
Descripción
Anticipated intracoronary brachytherapy
Tipo de datos
boolean
Alias
- UMLS CUI-1
- N
Descripción
Concurrent or anticipated treatment with warfarin
Tipo de datos
boolean
Alias
- UMLS CUI-1
- C0043031
Descripción
Concurrent or anticipated treatment with factor Xa inhibitor after enrollment
Tipo de datos
boolean
Alias
- UMLS CUI-1
- C2825027
Descripción
Concurrent or anticipated treatment with direct thrombin inhibitor after enrollment
Tipo de datos
boolean
Alias
- UMLS CUI-1
- C3536847
Descripción
Concurrent or anticipated treatment with or antiplatelet agents after enrollment
Tipo de datos
boolean
Alias
- UMLS CUI-1
- C1096021
Similar models
Eligibility criteria
- StudyEvent: ODM